Literature DB >> 24271357

Enhanced selective lymphatic delivery of cyclosporin a by solubilizers and intensified immunosuppressive activity against mice skin allograft.

K Takada1, H Yoshimura, H Yoshikawa, S Muranishi, T Yasumura, T Oka.   

Abstract

The absorption and lymphatic delivery of a new immunosuppressive drug, cyclosporin A (CsA), were studied in rats by administering CsA orally after solubilization with HCO-60 (polyoxyethylated hydrogenated castor oil), sugar ester, and oils. After the administration of solubilized CsA (7 mg/kg) to rats with thoracic lymph duct cannulas, both plasma and lymph CsA levels were measured over 6 hr. The lymph CsA levels were strongly affected by the solubilizers. The rank order of the solubilizers in enhancing lymph absorption was HCO-60 (57 µg/ml) > sugar ester (46 µg/ml) > sesame oil (3.5 µg/ml) > linoleic acid (0.4 µg/ml), where the parentheses show the maximum lymph CsA levels. Plasma CsA levels were below 2 µg/ml in each group of animals and were barely altered by the solubilizers. These results support the selective lymphatic delivery of CsA with solubilizers such as HCO-60 and sugar ester. The immunosuppressive activity of CsA (1 mg/kg) solubilized with HCO-60 was nearly equivalent to the sesame oil solution with 7 to 15 mg/kg CsA in the skin-allograft mice model.

Entities:  

Year:  1986        PMID: 24271357     DOI: 10.1023/A:1016324932378

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  The value of serial serum trough cyclosporine levels in human renal transplantation.

Authors:  B D Kahan; C A Wideman; M Reid; S Gibbons; M Jarowenko; S Flechner; C T Van Buren
Journal:  Transplant Proc       Date:  1984-10       Impact factor: 1.066

2.  A method to potentiate enteral absorption of interferon and selective delivery into lymphatics.

Authors:  H Yoshikawa; K Takada; S Muranishi; Y Satoh; N Naruse
Journal:  J Pharmacobiodyn       Date:  1984-01

Review 3.  Characteristics of drug absorption via the rectal route.

Authors:  S Muranishi
Journal:  Methods Find Exp Clin Pharmacol       Date:  1984-12

4.  Cyclosporin A hepatotoxicity in 66 renal allograft recipients.

Authors:  G B Klintmalm; S Iwatsuki; T E Starzl
Journal:  Transplantation       Date:  1981-12       Impact factor: 4.939

5.  Cyclosporine-associated chronic nephropathy.

Authors:  B D Myers; J Ross; L Newton; J Luetscher; M Perlroth
Journal:  N Engl J Med       Date:  1984-09-13       Impact factor: 91.245

6.  Amelioration of cyclosporin-induced nephrotoxicity in rats by induction of hepatic drug metabolism.

Authors:  C Cunningham; M D Burke; D N Wheatley; A W Thomson; J G Simpson; P H Whiting
Journal:  Biochem Pharmacol       Date:  1985-02-15       Impact factor: 5.858

7.  Intravenous cyclosporine kinetics in renal failure.

Authors:  F Follath; M Wenk; S Vozeh; G Thiel; F Brunner; R Loertscher; M Lemaire; K Nussbaumer; W Niederberger; A Wood
Journal:  Clin Pharmacol Ther       Date:  1983-11       Impact factor: 6.875

8.  Apparent dose-dependent oral absorption of cyclosporin A in rats.

Authors:  C T Ueda; M Lemaire; G Gsell; P Misslin; K Nussbaumer
Journal:  Biopharm Drug Dispos       Date:  1984 Apr-Jun       Impact factor: 1.627

9.  Pharmacokinetic evaluation of the blood-to-lymph transfer of cyclosporin A in rats.

Authors:  C T Ueda; M Lemaire; P Misslin
Journal:  Biopharm Drug Dispos       Date:  1983 Jan-Mar       Impact factor: 1.627

10.  High performance liquid chromatographic determination of cyclosporin A in body fluids.

Authors:  K Takada; N Shibata; H Yoshimura; H Yoshikawa; S Muranishi
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1985-06
View more
  1 in total

Review 1.  Distribution of cyclosporin in organ transplant recipients.

Authors:  Fatemeh Akhlaghi; Andrew K Trull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.